

2711

Dr Walford

AIDS

Further to my minute of 22 July 1983, we have completed the enquiries to the five companies to ascertain stocks held of blood products manufactured from plasma collected before March 1983. A summary of the replies received is attached as an Appendix A to this minute.

The variation in clearance dates for the old material quoted by the multi-product companies, Armour, Alpha Therapeutic and Immuno, relates to the stocks held of the different products. As we were previously advised, three of the companies, Miles, Armour and Alpha Therapeutic, introduced special screening programmes for donors prior to the new Food and Drug Administration regulations. (A copy has been received of the document describing the "Cutter System of Plasmapheresis" used by Miles Laboratories.)

I have attached for information at Appendix B a copy of a minute from Dr Fowler reporting the result of the recent Food and Drug Administration meeting. The decision taken at the meeting on products made before the implementation of the March 1983 regulations appears to conflict with the recommendation at (5) of the recent CSM paper. I should be glad of views on the further action, if any, now required on the stocks of pre-March 1983 material following the FDA decision, assuming this will not be overturned by the Congressional hearing.

GRO-C

2 August 1983

C WIGGLESWORTH
HSIB

RSQ

Ext GRO-C

cc Mr Parker HS1
Dr Oliver MEDSEB
Mr Sloggem STB
Miss Spencer MB
Mr Sharpe